



Figure Supplementary

A




120 month prognosis

B




240 month prognosis

**Fig. S1.** The survival analysis showed that low expression of PER3 was significantly associated with worse prognosis of breast cancer patients.



**Fig. S2.** The effect of PER3 expression on migratory ability of breast cancer cells was validated by wound healing assay.

MCF-7



**Fig. S3.** Flow cytometry analysis indicated that the silencing of PER3 had no effect on cell apoptosis of breast cancer.